Trials / Completed
CompletedNCT00170859
Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients
A One-year Multicenter, Randomized, Open-label Study of the Safety and Efficacy of Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- —
Summary
In this study two immunosuppressive regimens (everolimus in combination with cyclosporine microemulsion and mycophenolate mofetil with cyclosporine microemulsion) with reduced dose cyclosporine microemulsion are compared in maintenance heart transplant recipients with impaired renal function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Everolimus |
Timeline
- Start date
- 2004-08-01
- Primary completion
- 2006-11-01
- Completion
- 2006-12-01
- First posted
- 2005-09-15
- Last updated
- 2016-11-18
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00170859. Inclusion in this directory is not an endorsement.